44 / 56
HIPERTENSION / 2013 / VOL. 18
42
Bibliografía
1.
Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Comittee on Prevention, Detection, Evaluation and Treatment of High Blood
Pressure. Hypertension. 2003; 42:1206-52.
2.
Mancia G, Fagard R, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension
of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013, 31: 1281-1357.
3.
Kaplan N, Victor R. En: Hipertensión Clínica: Hipertensión en la población general. Décima Edición Wolters Kluwer Health España, S.A., Lippincott Williams
& Wilkins Barcelona; 2011,p:1-19.
4.
Ministerio de Salud de Chile. Encuesta Nacional de Salud 2010.
5.
Blumenfeld JD, Laragh JH. En: The Kidney. Brenner & Rector: Essential Hypertension. Seventh Edition Saunders; 2004, Vol. 2:2023-63.
6.
Domenic A, Sica. En: Hypertension, Secondary Hypertension. ACP key diseases series, 2005,p:167-187.
7.
Valtos J, Whaley-Connell et al. En: Hypertension, Hypertension in the Elderly. ACP key diseases series, 2005,p:221-229.
8.
Grossman E, Messerli FH. High Blood pressure a side effect of drug, poison, and food. Arch Inter Med 1995;155(5):450-60.
9.
Kaplan N, En: Hipertensión Clínica. Norman M. Kaplan: Otras formas de hipertensión secundaria. Tercera Edición Cayfosa-Quebecor Barcelona; 1999,p:496-498.
10.
Schwartz GL, Sheps SG. En: Webmed ACPMedicine. 1 Cardiovascular Medicine. III Hypertension; 2004.
11.
Grossman E, Messerli F. Drug-induced Hypertension: An unappreciated cause of secondary hypertension. The American Journal of Medicine 2012 JAN; 125
(1):15-22.
12.
Whitworth JA. Adrenocorticotropin and steroid-induces hypertension in humans. Kidney Int Suppl 1992 Jun; 37:S34-7.
13.
Saruta T; Suzuki H; Handa M; Igarashi Y; Kondo K; Senba S. Multiple factors contribute to the pathogenesis of hypertension in Cushing’s syndrome. J Clin
Endocrinol Metab 1986 Feb; 62(2):275-9.
14.
Jackson SH; Beevers DG; Myers K. Does long-term low-dose corticosteroid therapy cause hypertension? Clin Sci 1981 Dec; 61 Suppl 7:381s-383s.
15.
Pope JE; Anderson JJ; Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993 Feb 22;
153(4):477-84.
16.
Whelton A; Fort JG; Puma JA; Normandin D; Bello AE; Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled
trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001 Mar-Apr; 8(2):85-95.
17.
Sower JR et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension,
osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005 Jan 24; 165(2):161-8.updated meta-analysis. J Hypertension. 2009; 27(12):2332-2341.
18.
Chan CC, Reid CM et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updates meta-analysis. J Hypertens.
2009;27(12):2332-2341.
19.
Rose B; Kaplan N. NSAIDS and acetaminophen: Effects on blood pressure and hypertension. Uptodate in Medicine; Aug 2013.
20.
Brady HR, Clarkson MR and Lieberthal E. En: The Kidney Brenner & Rector: Acute Renal Failure. Seventh Edition Saunders; 2004, Vol. 1:1215-1292
21.
Liaño F, Pascual J. En: Nefrología Clínica L. Hernando Avendaño. Fracaso renal agudo: Concepto y epidemiología. Segunda Edición Madrid: Editorial Médica
Panamericana; 2003,p:637-38.
22.
Armstrong EP, Malone DC. The impact of nonesteroidal anti-inflamatory drugs on blood pressure, with an emphasis on newer agents. Clin Ther. 2003;25(1):1-18.
23.
Messeli F. Aspirin: a novel antihypertensive drug? Or two birds with one stone? J Am Coll Cardiol. 2005;46(6):984-985.
24.
Chasan – Taber L et al. Prospective study of oral contraceptive and hypertension among women in the United States. Circulation 1996 Aug 1; 94(3):483-9.
25.
Woods JW. Oral Contraceptives and hypertension. Hypertension 1988 Mar; 11(3 Pt 2):II11-5.
26.
Ribstein J, Halimi JM, du Cailar G, Mimran A. Renal Characteristics and effect of angiotensin suppression in oral contraceptive users. Hypertension 1999
Jan;33(1):90-5.
27.
Rossouw JE; Anderson GL et al. Risk and benefits of estrogen plus of progestin in healthy postmenopausal women: principal results from the Women’s Health
Initiative randomized controlled trial. JAMA 2002 Jul 17; 288(3):321-33.
28.
Anderson GL et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled
trial. JAMA 2004 Apr 14;291(14):1701-12.
29.
Hussain S. Progestagen-only pills and high blood pressure: is there an association? A literature review. Contraception. 2004;69(2):89-97.
30.
McMahon FG; Fujioka K et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind,
placebo-controlled, multicenter trial. Arch Intern Med 200 Jul 24; 160(14):2185-91.
31.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K. Sibutramine is safe and effective for weight loss in obese patients whose hypertension
is well controlled with angiotensin converting enzyme inhibitors. J Hum Hypertens 2002 Jan;16(1):5-11.
32.
First MR, Neylan JF, Rocher LL, Tejani AL. Hypertension after renal transplantation. J Am Soc Nephrol 1994 Feb;4(8 Suppl):S30-6.
33.
Textor SC; Canzanello VJ et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994 Dec;69(12):1182-93.
34.
Margreiter R. Efficacy and safety of tacrolimus compares with ciclosporine microemulsion in renal transplantation: a randomised multicenter study. Lancet
2002 Mar 2;359(9308):741-6.
35.
Grandominico J, Fichtenbaum C. Short-term effect of HAART on blood pressure in HIV-infected individuals. HIV Clin Trials. 2008;9(1):52-60.
36.
Crane H, Van Rompaey S, Kitahata M. Antiretroviral medications associates with elevated blood pressure among patients receiving highly active antiretroviral
therapy. AIDS. 2006;20(7):1019-1026.
estimulante del sistema nervioso central), digital (inotropismo cardiaco), ginseng (estimulante del
SNC, efecto glucocorticoideo)
(10)
.
Frente a cada caso en particular, debe analizarse la mejor alternativa terapéutica posible,
considerando la eventual participación de una droga o sustancia en la elevación de la PA, debiendo
ser indicada la suspensión del fármaco causal o la reducción de su dosis. En los casos en que esto
no es factible, se deberá agregar un tratamiento antihipertensivo racional.